Microsure

Executive Summary

Microsure is a Dutch medical device company pioneering high-precision robotic systems for microsurgery. Founded in 2016 and headquartered in Eindhoven, the company developed the MUSA platform, designed to enhance surgeon dexterity, filter tremors, and enable complex procedures such as lymphatico-venous anastomosis (LVA), free flap surgery, and nerve repair. By overcoming human limitations in microsurgery, Microsure aims to improve patient outcomes, particularly in reconstructive and lymphatic surgeries. The global microsurgery market is underserved by robotic solutions, and MUSA’s compact, modular design positions it as a cost-effective alternative to larger systems like da Vinci. With a strong IP portfolio and early clinical evidence, Microsure has attracted interest from leading surgical centers in Europe. The company is currently in a pivotal phase, transitioning from pilot studies to broader commercial adoption. Microsure has received CE marking for MUSA and is pursuing FDA clearance to enter the U.S. market. Its success hinges on demonstrating clinical efficacy, securing reimbursement, and building a robust distribution network. With increasing adoption of minimally invasive techniques, Microsure is well-positioned to capture a niche but growing segment. However, competition from established players and the need for surgeon training may temper near-term growth. Overall, the company’s innovative approach and clear clinical value proposition warrant a conviction score of 75.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for MUSA System70% success
• Q3 2026Publication of Pivotal Clinical Study Results in Major Journals60% success
• Q2 2026Strategic Partnership with Global Medical Device Distributor50% success